Shandong Province Qianfoshan Hospital Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Jinan China (1960)

Organization Overview

First Clinical Trial
2008
NCT03030300
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Lili Cao | Lin Liao | Qianfoshan Hospital | Shandong Provincial Qianfoshan Hospital | Shandong Qianfo Hospital | Shandong Qianfoshan Hospital

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Delirium (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Heart Failure (Phase 3)

Heart Failure, Systolic (Phase 3)

Hepatoblastoma (Phase 4)

Hip Fractures (Phase 4)

Hypersensitivity (Phase 4)

Leprosy (Phase 4)

Leukemia (Phase 4)

Leukemia, Lymphoid (Phase 4)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Neoplasm Metastasis (Phase 4)

Neuroblastoma (Phase 4)

Pneumonia, Pneumocystis (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Recurrence (Phase 4)

Retinoblastoma (Phase 4)

Skin Diseases (Phase 4)

Skin Diseases, Vesiculobullous (Phase 4)

Thrombocytopenia (Phase 3)

Thyroid Diseases (Phase 4)

Thyroid Neoplasms (Phase 4)

Urticaria (Phase 4)

Vasculitis (Phase 4)

Vasculitis, Leukocytoclastic, Cutaneous (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 31
  • # of Trial APIs: 42